Lipocine Inc. — Q2 2016 Form 10-Q
Business context and reporting period. Lipocine is a clinical-stage specialty pharmaceutical company developing oral drug-delivery products, primarily for men’s and women’s health. This unaudited report covers the quarter and six months ended June 30, 2016. The company had no product-sales revenue and reported no debt.
Financial results and liquidity
| Metric | Three months ended June 30, 2016 | Six months ended June 30, 2016 | Comparable 2015 period |
|---|---|---|---|
| Revenue | No product-sales revenue | No product-sales revenue | No product-sales revenue |
| Research and development | $2.57 million | $5.24 million | $3.16 million / $5.08 million |
| General and administrative | $3.25 million | $7.64 million | $1.12 million / $2.17 million |
| Operating loss | $5.82 million | $12.89 million | $4.28 million / $7.25 million |
| Net loss | $5.76 million | $12.77 million | $4.25 million / $7.20 million |
| Loss per share, basic and diluted | $0.32 | $0.70 | $0.26 / $0.49 |
| Operating cash used | — | $11.69 million | $6.89 million |
As of June 30, cash and cash equivalents were $12.37 million and marketable securities were $20.57 million, totaling $32.94 million. Total current liabilities were $2.58 million and total stockholders’ equity was $30.76 million. The filing reports no borrowings. Cash and cash equivalents declined $7.63 million in the first half; investing activities provided $4.02 million, while financing activities provided $34,000. No meaningful operating margin is available because the company had no product-sales revenue.
Changes versus the prior comparable period
- First-half net loss increased to $12.77 million from $7.20 million; operating expenses rose to $12.89 million from $7.25 million.
- First-half G&A increased $5.47 million, primarily due to pre-commercialization spending, higher personnel and stock-based compensation costs, and patent litigation costs.
- First-half R&D increased modestly by $160,000: higher LPCN 1021 validation-batch manufacturing and personnel costs were partly offset by lower contract research and consultant costs.
- First-half operating cash use rose to $11.69 million from $6.89 million. The 2015 comparison included $32.5 million of net proceeds from a common-stock offering; there was no stock offering in the first half of 2016.
Outlook, developments, and risks
- LPCN 1021: The FDA issued a Complete Response Letter on June 28, 2016, identifying concerns about the proposed label titration algorithm and its mismatch with the Phase 3 trial titration scheme. Lipocine planned to reanalyze existing data and request an FDA End-of-Review meeting in Q3 2016. The FDA could require additional studies or trials, and approval is not assured. The company estimated approximately $1.6 million in additional LPCN 1021 R&D costs for CRL analysis, meeting preparation, and committed manufacturing activities.
- Pipeline: LPCN 1111 was in a Phase 2b dose-finding study, with top-line results expected in Q3 2016. LPCN 1107 had completed Phase 1 work; an End-of-Phase 2 FDA meeting was expected in Q3 2016 to discuss a potential Phase 3 plan. These milestones are forward-looking expectations, not reported outcomes.
- Liquidity and funding: Management believed available resources would fund projected operating requirements for at least 12 months, and stated it believed resources were sufficient through June 30, 2017. This estimate depends on assumptions and could change with FDA requirements, development plans, or commercialization decisions. The company said it would need additional capital for longer-term operations and had no credit facility or committed financing.
- Cost actions: After quarter-end, the board approved a July 2016 reduction in force of eight employees, approximately 33% of the workforce. Estimated cash expenditures were about $370,000, primarily severance; estimated restructuring expense was $135,000, with most expected in Q3 2016. Management expected lower expenses through year-end, while noting future costs depend on development and regulatory needs.
- Legal and other contingencies: Clarus litigation alleges LPCN 1021 would infringe a patent; the court magistrate recommended denial of Lipocine’s motion to dismiss, and Lipocine objected. A patent interference proceeding had oral argument scheduled for September 9, 2016. The company and certain officers also faced purported shareholder class actions following the FDA CRL; claimed damages were unspecified. No litigation contingency was accrued at June 30 because management did not consider any contingency probable and estimable.
- The company disclosed a perpetual 1% royalty to Abbott on net sales of LPCN 1021, with a $1 million cap during the first two calendar years after launch and no cap thereafter; no royalties had been incurred. The filing also describes related-party arrangements with Spriaso and future operating lease commitments of $635,572.
Key facts for investors to verify
- What the FDA requests or agrees to at the LPCN 1021 End-of-Review meeting, including whether additional clinical work is required and the expected time and cost to approval.
- Whether the anticipated Q3 2016 LPCN 1111 and LPCN 1107 milestones occurred, and what they imply for each program’s development plan and funding needs.
- Actual cash burn and remaining liquidity after the workforce reduction, ongoing manufacturing commitments, and any new FDA requirements; the runway estimate is assumption-dependent.
- Developments and potential financial exposure in the Clarus patent proceedings and shareholder lawsuits, including insurance coverage and litigation costs.
- Share-based compensation and dilution: first-half stock-based compensation was $1.47 million, and 2.29 million stock options were outstanding at June 30, 2016.